These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 17002926

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT, Safi W, Trinh H.
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risedronate: a new oral bisphosphonate.
    Umland EM, Boyce EG.
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [Abstract] [Full Text] [Related]

  • 12. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M.
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
    Bae SJ, Kim BJ, Lim KH, Lee SH, Kim HK, Kim GS, Koh JM.
    J Bone Miner Metab; 2012 Sep; 30(5):588-95. PubMed ID: 22610063
    [Abstract] [Full Text] [Related]

  • 14. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S, Olson M, van Staa TP.
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [Abstract] [Full Text] [Related]

  • 15. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT, Trinh H, Safi W.
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [Abstract] [Full Text] [Related]

  • 16. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD, Ettinger M.
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 18. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
    Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W.
    Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
    [Abstract] [Full Text] [Related]

  • 19. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M, Abrahamsen B, Wang Y, Russell RG.
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [Abstract] [Full Text] [Related]

  • 20. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R.
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.